Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel (Q43225374)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 March 2013

edit

Language	Label	Description	Also known as
English	Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel	scientific article published on 9 March 2013

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

case report

0 references

title

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

main subject

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

dasatinib

1 reference

based on heuristic

inferred from title

author name string

John C Araujo

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

Geralyn C Trudel

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

Prashni Paliwal

series ordinal

3

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

language of work or name

English

0 references

publication date

9 March 2013

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

published in

Cancer Management and Research

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

volume

6

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

page(s)

25-30

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

start time

1 March 2013

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Emerging targeted therapies for castration-resistant prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Minireview: Alternative activation pathways for the androgen receptor in prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Guidelines for the management of castrate-resistant prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Targeting the androgen receptor pathway in prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Regulation of androgen receptor activity by tyrosine phosphorylation.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

25 May 2018

The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

15 August 2018

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601649

retrieved

15 August 2018

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23516140

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23516140

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.2147/CMAR.S41667

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

PMC publication ID

3601649

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

PubMed publication ID

23516140

1 reference

stated in

Europe PubMed Central

PMC publication ID

3601649

retrieved

16 November 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43225374&oldid=1984173345"